

# SSD Immunologia Traslazionale

## Elenco pubblicazioni 2021-2023

- 1 - Rivoltini L, Bhoori S, Camisaschi C, Bergamaschi L, Lalli L, Frati P, Citterio D, Castelli C, Mazzaferro V. Y90-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers. *Gut* 2023;72:406-407
- 2 - Kusamura S, Busico A, Conca E, Capone I, Agnelli L, Lorenzini D, Brich S, Angelini M, Volpi Cc, Trupia Dv, Lagano V, Torelli T, Gloghini A, Baratti D, Guaglio M, Milione M, Deraco M, Perrone F. A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei. *Biomedicines* 2023;11:
- 3 - Guzzetti C, Corno C, Vergani E, Mirra L, Ciusani E, Rodolfo M, Perego P, Beretta Gl. Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells. *Frontiers In Oncology* 2023;13:1182853
- 4 - Vandoni G, D'amico F, Fabbrini M, Mariani L, Sieri S, Casirati A, Di Guardo L, Del Vecchio M, Anichini A, Mortarini R, Sgambelluri F, Celano G, Serale N, De Angelis M, Brigidi P, Gavazzi C, Turroni S. Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma. *International Journal Of Molecular Sciences* 2023;24:
- 5 - Noviello Tmr, Di Giacomo Am, Caruso Fp, Covre A, Mortarini R, Scala G, Costa Mc, Coral S, Fridman Wh, Sautès Fridman C, Brich S, Pruneri G, Simonetti E, Lofiego Mf, Tufano R, Bedognetti D, Anichini A, Maio M, Ceccarelli M. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. *Nature Communications* 2023;14:5914
- 6 - Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, FucÀ G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi Ca, Lalli L, Boldrini L, Giacchetti Ppb, Schianca Ac, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali D, Criscitiello C, Curigliano G, Pruneri G, De Braud F, Dieci Mv, Vernieri C. Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. *Npj Breast Cancer* 2023;9:27
- 7 - Cattaneo L, Centonze G, Sabella G, Lagano V, Angerilli V, Pardo C, Bertani E, Spada F, Prinzi N, Pusceddu S, Fassan M, Fazio N, Milione M. Digestive MiNENs: Could histological classification and molecular characterization drive clinical outcome and therapeutic approach? *Critical Reviews In Oncology Hematology* 2023;188:104044
- 8 - Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnolletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi Alg, Trovo' F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, Mcculloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino Mc. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: A multiomics analysis. *Journal For Immunotherapy Of Cancer* 2023;11:
- 9 - Sorrentino L, Sileo A, Daveri E, Battaglia L, Guaglio M, Centonze G, Sabella G, Patti F, Villa S, Milione M, Belli F, Cosimelli M. Impact of Microscopically Positive ( $\leq$ 1 mm) Distal Margins on Disease Recurrence in Rectal Cancer Treated by Neoadjuvant Chemoradiotherapy. *Cancers* 2023;15:
- 10 - Centonze G, Maisonneuve P, Simbolo M, Lagano V, Grillo F, Fabbri A, Prinzi N, Garzone G, Filugelli M, Pardo C, Mietta A, Pusceddu S, Sabella G, Bercich L, Mangogna A, Rolli L, Grisanti

S, Benvenuti Mr, Pastorino U, Roz L, Scarpa A, Berruti A, Capella C, Milione M. Lung carcinoid tumours: histology and Ki-67, the eternal rivalry. *Histopathology* 2023;82:324-339

- 11 - Centonze G, Maisonneuve P, Simbolo M, Lagano V, Grillo F, Prinzi N, Pusceddu S, Missiato L, Colantuono M, Sabella G, Bercich L, Mangogna A, Rolli L, Grisanti S, Benvenuti Mr, Pastorino U, Roz L, Scarpa A, Berruti A, Capella C, Milione M. Ascl1 and OTP tumour expressions are associated with disease-free survival in lung atypical carcinoids. *Histopathology* 2023;82:870-884
- 12 - Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PI, Morrone A, Notari S, Matusali G, Pinter GI, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo Stanghellini Mt, Apolone G, Vax4frail Study Group {corradi P, Mortarini R, Damian S, Marasco V, De Braud F, Di Cosimo S, Pulice I}. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters. *Frontiers In Immunology* 2023;14:1104124
- 13 - Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordoni V, Sacchi A, Matusali G, Salvarani C, Zinzani PI, Mantegazza R, Tagliavini F, Lupo Stanghellini Mt, Ciceri F, Damian S, Uccelli A, Fenoglio D, Silvestris N, Baldanti F, Piaggio G, Ciliberto G, Morrone A, Locatelli F, Sinno V, Rescigno M, Costantini M, Vax4frail Study Group {mortarini R, De Braud F, Di Cosimo S, Pulice I}. Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. *Clinical Infectious Diseases* 2023;76:e426-e438
- 14 - Huber V, Vallacchi V, Daveri E, Vergani E. 3D models for melanoma γδ T cell-based immunotherapy. *Clinical And Translational Medicine* 2022;12:e926
- 15 - Rodolfo M, Huber V, Cossa M, Gallino G, Leone Be, Vallacchi V, Rivoltini L, Vergani E. 3D tumor explant as a novel platform to investigate therapeutic pathways and predictive biomarkers in cancer patients. *Frontiers In Immunology* 2022;13:1068091
- 16 - Orlandi E, De Tomi E, Campagnari R, Belpinati F, Rodolfo M, Vergani E, Malerba G, Gomez Lira M, Menegazzi M, Romanelli Mg. Human Melanoma Cells Differentially Express RNASEL/RNase-L and miR-146a-5p under Sex Hormonal Stimulation. *Current Issues In Molecular Biology* 2022;44:4790-4802
- 17 - Vergani E, Daveri E, Vallacchi V, Bergamaschi L, Lalli L, Castelli C, Rodolfo M, Rivoltini L, Huber V. Extracellular vesicles in anti-tumor immunity. *Seminars In Cancer Biology* 2022;86:64-79
- 18 - Fortunato O, Huber V, Segale M, Cova A, Vallacchi V, Squarcina P, Rivoltini L, Suatoni P, Sozzi G, Pastorino U, Boeri M. Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening. *Cancer Epidemiology Biomarkers & Prevention* 2022;31:2020-2029
- 19 - Anichini A, Molla A, Nicolini G, Perotti Ve, Sgambelluri F, Covre A, Fazio C, Lofiego Mf, Di Giacomo Am, Coral S, Manca A, Sini Mc, Pisano M, Noviello T, Caruso F, Brich S, Pruner G, Maurichi A, Santinami M, Ceccarelli M, Palmieri G, Maio M, Mortarini R, Epigenetic Immune Oncology Consortium Airc (epica) Investigators. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. *Journal Of Experimental & Clinical Cancer Research* 2022;41:325
- 20 - Lo Russo G, Sgambelluri F, Prelaj A, Galli F, Manglaviti S, Bottiglieri A, Di Mauro Rm, Ferrara R, Galli G, Signorelli D, De Toma A, Occhipinti M, Brambilla M, Rulli E, Triulzi T, Torelli T, Agnelli L, Brich S, Martinetti A, Dumitrescu Ad, Torri V, Pruner G, Fabbri A, De Braud F, Anichini A, Proto C, Ganzinelli M, Mortarini R, Garassino Mc. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. *Esmo Open* 2022;7:100645
- 21 - Fucà G, Lecchi M, Ciniselli Cm, Ottini A, Spagnoletti A, Mazzeo L, Morelli D, Frati P, Stroscia M, Ebrahem E, Sottotetti E, Galli G, D'elia Mg, Lobefaro R, Ducceschi M, Di Guardo L, Bhoori S,

Provenzano S, Platania M, Niger M, Colombo E, Nichetti F, Duca M, Rivoltini L, Mortarini R, Baili P, Apolone G, De Braud F, Verderio P, Damian S. Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center. *Therapeutic Advances In Medical Oncology* 2022;14:1.75883592211086E+16

- 22 - Vergani E, Beretta GI, Aloisi M, Costantino M, Corno C, Frigerio S, Tinelli S, Dugo M, Accattatis Fm, Granata A, Arnaboldi L, Rodolfo M, Perego P, Gatti L. Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma. *Frontiers In Cell And Developmental Biology* 2022;10:927118
- 23 - IannÓ Mf, Biassoni V, Schiavello E, Carenzo A, Boschetti L, Gandola L, Diletto B, Marchesi E, Vegetti C, Molla A, Kramm Cm, Van Vuurden Dg, Gasparini P, Gianno F, Giangaspero F, Modena P, Bison B, Anichini A, Vennarini S, Pignoli E, Massimino M, De Cecco L. A microRNA Prognostic Signature in Patients with Diffuse Intrinsic Pontine Gliomas through Non-Invasive Liquid Biopsy. *Cancers* 2022;14:14174307
- 24 - Sorrentino L, Daveri E, Sabella G, Battaglia L, Milione M, Rivoltini L, Cosimelli M. Pathologic complete response after neoadjuvant chemotherapy/(re)chemoradiation for pelvic relapse of rectal cancer undergoing complex pelvic surgery: more frequent than expected? *International Journal Of Colorectal Disease* 2022;37:2257-2261
- 25 - Vergani E, Busico A, Dugo M, Devecchi A, Valeri B, Cossa M, Di Guardo L, De Cecco L, Feltrin E, Valle G, Deho P, Frigerio S, Lalli L, Gallino G, Del Vecchio M, Santinami M, Pruner G, Tamborini E, Rivoltini L, Sensi M, Vallacchi V, Rodolfo M. Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. *Journal Of Investigative Dermatology* 2022;142:3030-3040.e5
- 26 - Bogani G, Lalli L, Sopracordevole F, Ciavattini A, Ghelardi A, Simoncini T, Plotti F, Casarin J, Serati M, Pinelli C, Bergamini A, Gardella B, Dell'acqua A, Monti E, Vercellini P, Palaia I, Perniola G, Fischetti M, Santangelo G, Fracassi A, D'ippolito G, Aguzzoli L, Mandato Vd, Giannella L, Scaffa C, Falcone F, Borghi C, Malzoni M, Giannini A, Salerno Mg, Liberale V, Contino B, Donfrancesco C, Desiato M, Perrone Am, Dondi G, De Iaco P, Ferrero S, Sarpietro G, Matarazzo Mg, Cianci A, Cianci S, Bosio S, Ruisi S, Mosca L, Tinelli R, De Vincenzo R, Zannoni Gf, Ferrandina G, Petrillo M, Capobianco G, Dessole S, Carlea A, Zullo F, Muschiato B, Palomba S, Greggi S, Spinillo A, Ghezzi F, Colacurci N, Angioli R, Benedetti Panici P, Muzii L, Scambia G, Raspagliesi F, Di Donato V. Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical Dysplasia. *Vaccines* 2022;10:10040579
- 27 - Procopio G, Sepe P, Claps M, Buti S, Colecchia M, Giannatempo P, Guadalupi V, Mariani L, Lalli L, FucÀ G, De Braud F, Verzoni E. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). *Jama Oncology* 2022;8:910-913
- 28 - Paolino G, Buratta S, Mercuri Sr, Pellegrino Rm, Urbanelli L, Emiliani C, Bertuccini L, Iosi F, Huber V, Brianti P, Prezioso C, Di Nicola Mr, Federici C, Lugini L. Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients. *Frontiers In Cell And Developmental Biology* 2022;10:923769
- 29 - Vernieri C, FucÀ G, Ligorio F, Huber V, Vingiani A, Iannelli F, Raimondi A, Rinchai D, Frigè G, Belfiore A, Lalli L, Chiodoni C, Cancila V, Zanardi F, Ajazi A, Cortellino S, Vallacchi V, Squarcina P, Cova A, Pesce S, Frati P, Mall R, Corsetto Pa, Rizzo Am, Ferraris C, Folli S, Garassino Mc, Capri G, Bianchi G, Colombo Mp, Minucci S, Foiani M, Longo Vd, Apolone G, Torri V, Pruner G, Bedognetti D, Rivoltini L, De Braud F. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. *Cancer Discovery* 2022;12:90-107
- 30 - Daveri E, Sorrentino L, Lalli L, Guaglio M, Battaglia L, Cattaneo L, Sabella G, Milione M, Rivoltini L, Cosimelli M, Belli F. Low baseline neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios

predict increased overall survival in locally recurrent rectal cancer despite R1 margins. *Digestive And Liver Disease* 2022;54:864-870

- 31 - Pellegrini C, Raimondi S, Di Nardo L, Ghiorzo P, Menin C, Manganoni Ma, Palmieri G, Guida G, Quaglino P, Stanganelli I, Massi D, Pastorino L, Elefanti L, Tosti G, Queirolo P, Leva A, Maurichi A, Rodolfo M, Farnoli Mc, Italian Melanoma Intergroup (imi) {ferrari A, Frigerio S, Valeri B}. Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. *Journal Of The European Academy Of Dermatology And Venereology* 2022;36:213-221
- 32 - Raab Wj, Mazzocchi A, Radice P, Sahoo D, Castelli C, Dalerba P, Colon Cancer Immunology And Immunotherapy (ccii) Study Group {lombardo C, Arienti F, Parmiani G}. A Microsatellite in the Coding Sequence of HLA-A/B Is a Mutation Hotspot in Colon Cancer With Microsatellite Instability. *Gastroenterology* 2022;162:960-963.e3
- 33 - Creemers Jha, Pawlitzky I, Grosios K, Gileadi U, Middleton Mr, Gerritsen Wr, Mehra N, Rivoltini L, Walters I, Figdor Cg, Ottevanger Pb, De Vries Ijm. Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: A first-in-human phase i open-label dose-escalation study protocol. *Bmj Open* 2021;11:e050725
- 34 - Di Guardo L, Randon G, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, De Braud F, Rodolfo M, Vecchio Md. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. *Oncologist* 2021;26:1079-1084
- 35 - Ciniselli Cm, Bruno E, Oliverio A, Baldassari I, Pastori M, Signoroni S, Vitellaro M , Ricci Mt , Milione M , Cattaneo L, Gariboldi M, Mancini A, Rivoltini L , Morelli D , Pasanisi P , Verderio P. Management of dietary habits and diarrhea in fap individuals: A mediterranean low-inflammatory dietary intervention. *Nutrients* 2021;13:3988
- 36 - Belfiore A, Ciniselli Cm, Signoroni S, Gariboldi M, Mancini A, Rivoltini L, Morelli D, Masci E, Bruno E, Macciotta A, Ricci Mt, Daveri E, Cattaneo L, Gargano G, Apolone G, Milione M, Verderio P, Pasanisi P, Vitellaro M. Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study. *Cancer Prevention Research* 2021;14:963-972
- 37 - Rinchia D, Verzoni E, Huber V, Cova A, Squarcina P, De Cecco L, De Braud F, Ratta R, Dugo M, Lalli L, Vallacchi V, Rodolfo M, Roelands J, Castelli C, Chaussabel D, Procopio G, Bedognetti D, Rivoltini L. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. *Clinical And Translational Medicine* 2021;11:e434
- 38 - Vergani E, Frigerio S, Dugo M, Devecchi A, Feltrin E, De Cecco L, Vallacchi V, Cossa M, Di Guardo L, Manoukian S, Peissel B, Ferrari A, Gallino G, Maurichi A, Rivoltini L, Sensi M, Rodolfo M. Genetic variants and somatic alterations associated with MITF-E318K germline mutation in melanoma patients. *Genes* 2021;12:
- 39 - Nichetti F, Ligorio F, Montelatici G, Porcu L, Zattarin E, Provenzano L, Franzia A, Lalli L, De Braud F, Platania M. Risk assessment of thromboembolic events in hospitalized cancer patients. *Scientific Reports* 2021;11:18200
- 40 - Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi Ca, Griguolo G, Marra A, Randon G, Rea Cg, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruner G, Mariani L, De Braud F. Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with

hormone receptor-positive advanced breast cancer (EVERMET). Clinical Cancer Research 2021;27:3443-3455

- 41 - Fucà G, Ambrosini M, Agnelli L, Brich S, Sgambelluri F, Mortarini R, Pupa Sm, Magni M, Devizzi L, Matteucci P, Cabras A, Zappasodi R, De Santis F, Anichini A, De Braud F, Gianni Am, Di Nicola M. Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. Journal For Immunotherapy Of Cancer 2021;9:
- 42 - Torchio M, Cattaneo L, Milione M, Prinzi N, Corti F, Ungari M, Anichini A, Mortarini R, Occhini A, Bertino G, Maurichi A, Coppa J, Di Bartolomeo M, De Braud Fg, Pusceddu S. Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma. Frontiers In Oncology 2021;11:628324
- 43 - Tazzari M, Bergamaschi L, De Vita A, Collini P, Barisella M, Bertolotti A, Ibrahim T, Pasquali S, Castelli C, Vallacchi V. Molecular determinants of soft tissue sarcoma immunity: Targets for immune intervention. International Journal Of Molecular Sciences 2021;22:
- 44 - Mainini F, De Santis F, Fucà G, Di Nicola M, Rivoltini L, Eccles M. Nanobiotechnology and immunotherapy: Two powerful and cooperative allies against cancer. Cancers 2021;13:
- 45 - Paolino G, Huber V, Camerini S, Casella M, Macone A, Bertuccini L, Iosi F, Moliterni E, Cecchetti S, Ruspantini I, Chiarotti F, Vergani E, Lalli L, Raggi C, Di Biase A, Calvieri S, Mercuri Sr, Lugini L, Federici C. The fatty acid and protein profiles of circulating cd81-positive small extracellular vesicles are associated with disease stage in melanoma patients. Cancers 2021;13:
- 46 - Daveri E, Adamo Am, Alfine E, Zhu W, Oteiza Pi. Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway. Redox Biology 2021;38:101830
- 47 - Huber V, Di Guardo L, Lalli L, Giardiello D, Cova A, Squarcina P, Frati P, Di Giacomo Am, Pilla L, Tazzari M, Camisaschi C, Arienti F, Castelli C, Rodolfo M, Beretta V, Di Nicola M, Maio M, Del Vecchio M, De Braud F, Mariani L, Rivoltini L. Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. Journal For Immunotherapy Of Cancer 2021;9:
- 48 - Fochi S, Orlandi E, Ceccuzzi L, Rodolfo M, Vergani E, Turco A, Romanelli Mg, Gomez-lira M. Identification of suitable mRNAs and microRNAs as reference genes for expression analyses in skin cells under sex hormone exposure. Gene 2021;769:145336
- 49 - Casirati A, Vandoni G, Della Valle S, Greco G, Platania M, Colatruglio S, Lalli L, Gavazzi C. Nutritional status and body composition assessment in patients with a new diagnosis of advanced solid tumour: Exploratory comparison of computed tomography and bioelectrical impedance analysis. Clinical Nutrition 2021;40:1268-1273
- 50 - Sorrentino L, Belli F, Guaglio M, Daveri E, Cosimelli M. Prediction of R0/R+ surgery by different classifications for locally recurrent rectal cancer. Updates In Surgery 2021;73:539-545
- 51 - Consonni Fm, Bleve A, Totaro Mg, Storto M, Kunderfranco P, Termanini A, Pasqualini F, Alì C, Pandolfo C, Sgambelluri F, Grazia G, Santinami M, Maurichi A, Milione M, Erreni M, Doni A, Fabbri M, Gribaldo L, Rulli E, Soares Mp, Torri V, Mortarini R, Anichini A, Sica A. Heme catabolism by tumor-associated macrophages controls metastasis formation. Nature Immunology 2021;22:595-606
- 52 - Stamatakos S, Beretta Gl, Vergani E, Dugo M, Corno C, Corna E, Tinelli S, Frigerio S, Ciusani E, Rodolfo M, Perego P, Gatti L. Deregulated FASN expression in BRAF inhibitor-resistant melanoma cells unveils new targets for drug combinations. Cancers 2021;13:

53 - Daveri E, Luison E, Vallacchi V, Vergani B, Leone Be, Garassino Mc, Figini M, Rivoltini L. Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes? Annals Of Oncology 2021;32:814-816